May 14 (Reuters) - Biohaven Ltd BHVN.N:
FDA EXTENDS PDUFA DATE OF BIOHAVEN'S TRORILUZOLE NDA FOR RARE DISEASE SPINOCEREBELLAR ATAXIA
BIOHAVEN LTD - FDA'S DECISION REGARDING NDA IS NOW EXPECTED IN 4Q 2025.
Source text: ID:nPn6YwSwKa
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))